By Marie Rosenthal
The FDA approved cladribine (Mavenclad, EMD Serono) tablets to treat relapsing forms of multiple sclerosis (MS) in adults, to include relapsing-remitting MS and active secondary progressive MS (SPMS).
Cladribine is given once annually for two years. Following the administration of two treatment courses, additional courses of cladribine are not to be administered because of a greater risk for malignancy. The safety and efficacy of reinitiating cladribine more than two